There is also considerable clinical interest in the use of neurofilament proteins as biomarkers of axonal damage in diseases affecting the central nervous system When neurons or axons degenerate, neurofilament proteins are released into the blood or cerebrospinal fluid. Immunoassays of neurofilament proteins in cerebrospinal fluid and plasma can thus serve as indicators of axonal damage in neurological disorders. NfL is a useful marker for disease monitoring in amyotrophic lateral sclerosis, multiple sclerosis, and more recently Huntington's disease. It has also been evaluated as a prognostic marker for functional outcome following acute ischemic stroke